Executive leadership at BIOVIE.
Board of directors at BIOVIE.
Research analysts covering BIOVIE.
Recent press releases and 8-K filings for BIVI.
BioVie under investigation by Bragar Eagel & Squire, P.C.
BIVI
Legal Proceedings
- Bragar Eagel & Squire, P.C. is investigating BioVie Inc. (BIVI) for potential claims against its board of directors regarding breach of fiduciary duties.
- This investigation follows a class action complaint filed on January 19, 2024, covering a Class Period from August 5, 2021, to November 29, 2023.
- The claims stem from BioVie's November 29, 2023, disclosure of top-line data from its NE3107 clinical trial, which revealed significant protocol deviations and Good Clinical Practice (GCP) violations at 15 sites.
- Due to patient exclusions, the Phase 3 clinical trial did not achieve statistical significance, leading to a more than 60% drop in BioVie's share price to $1.96 per share on November 29, 2023.
Oct 9, 2025, 2:18 PM
BioVi Updates on Clinical Pipeline Progress and Financial Runway
BIVI
New Projects/Investments
Guidance Update
- BioVi anticipates full enrollment for its Phase II Parkinson's trial by the end of 2025, with top-line data expected in April or May 2026.
- The company's Phase II Long COVID trial is enrolling well, with data readout projected for mid-2026, backed by a $13 million grant.
- BioVi submitted its Phase III protocol for the ascites clinical trial to the FDA three weeks prior to October 8, 2025, expecting a response by the end of next week.
- BioVi maintains a significant cash runway, extending to 2026, which covers the expected data readouts for its Parkinson's and Long COVID trials.
- The estimated annual market potential for BioVi's ascites drug (BIV201) in the U.S. is between $1.6 billion and $2 billion.
Oct 8, 2025, 8:15 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more